Litchfield Hills analyst Theodore O’Neill initiated coverage of SHL Telemedicine with a Buy rating and $11 price target. The analyst says SHL is a pure-play in the “rapidly expanding” $115B telemedicine market. The firm views the shares as undervalued says the company has established itself as a leader in the telemedicine landscape.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>